FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection By Ogkologos - January 14, 2026 398 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the PALOMA-3 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR 40 K9 Officers Line Up Outside Terminally Ill Girl’s House For... March 26, 2019 Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC June 6, 2025 Nurse Who Battled Cancer While In School Surprises Her Dad With... March 1, 2021 Got the COVID Blues? August 12, 2020 Load more HOT NEWS Man Who Lost His Mother to Breast Cancer Opens Resource Center... COVID-19 Is Decimating Nursing Homes, So GreaterGood Has Donated Masks To... Cancer in My Community: Improving Access to Palliative Care in Indonesia NECTIN4 Amplification Predicts Response to Enfortumab Vedotin and Long-Term Survival in...
